CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab
With CANTOS, Novartis's canakinumab has become the first investigational treatment to show that selectively targeting inflammation significantly reduces cardiovascular risk, albeit modestly, but with the added bonus of reducing lung cancer.
You may also be interested in...
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.
NIBR's Bradner talked to Scrip about how AveXis turbo-charged Novartis' gene therapy development, investing in inflammasome research, and partnering nimbly like a venture capitalist.
Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.